Last Updated: August 9, 2026

Details for Patent: 9,527,833


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,527,833 protect, and when does it expire?

Patent 9,527,833 protects LONSURF and is included in one NDA.

This patent has fifty-one patent family members in thirty countries.

Summary for Patent: 9,527,833
Title:Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Abstract:An objective of the present invention is to obtain a stable crystal form of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride. The present invention provides a crystal of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride exhibiting characteristic peaks at angles of 11.6°, 17.2°, 17.8°, 23.3°, 27.1°, and 29.3° as a diffraction angle (2θ±0.1°) in powder X-ray diffraction.
Inventor(s):Hideki Kazuno, Tomonobu MUTSUMI
Assignee: Taiho Pharmaceutical Co Ltd
Application Number:US14/896,748
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,527,833
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent landscape, scope, and claims:

error: insufficient information

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,527,833

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Taiho Oncology LONSURF tipiracil hydrochloride; trifluridine TABLET;ORAL 207981-001 Sep 22, 2015 AB RX Yes No 9,527,833 ⤷  Start Trial Y Y ⤷  Start Trial
Taiho Oncology LONSURF tipiracil hydrochloride; trifluridine TABLET;ORAL 207981-002 Sep 22, 2015 AB RX Yes Yes 9,527,833 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,527,833

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2013-126567Jun 17, 2013
PCT Information
PCT FiledJune 17, 2014PCT Application Number:PCT/JP2014/065985
PCT Publication Date:December 24, 2014PCT Publication Number: WO2014/203877

International Family Members for US Patent 9,527,833

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014282281 ⤷  Start Trial
Australia 2017208215 ⤷  Start Trial
Australia 2018219967 ⤷  Start Trial
Brazil 112015031619 ⤷  Start Trial
Canada 2914999 ⤷  Start Trial
Canada 2985006 ⤷  Start Trial
China 104395307 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.